CCR4 and ovarian carcinoma: CCR4-expressing Tregs were shown to be attracted to CCL22 released by macrophages within ovarian cancer, which was associated with a decreased survival rate (39), and the anti-CCR4 mAb Mogamulizumab effectively depleted effector Tregs in humans to elicit anticancer response (61), which is now being trialed alone or in combination with ICIs in solid tumors (62).